PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

This study is testing a combination of two drugs — palbociclib (a targeted drug that slows cell division) and avelumab (an immunotherapy drug) — in patients with a hard-to-treat form of breast cancer called androgen receptor-positive (AR+) triple-negative breast cancer. Triple-negative breast cancer does not respond to hormone therapies or HER2-targeted treatments, making new approaches urgently needed. **You may be eligible if:** - You have locally advanced or metastatic (spread) breast cancer that cannot be removed with surgery - You have been treated with at least one but no more than two prior chemotherapy regimens for advanced disease - If your cancer is ER-positive, you have also received at least one hormone therapy; if HER2-positive, at least one HER2-targeted therapy - Your cancer can be measured on imaging scans - Your blood counts and organ function are within required ranges **You may NOT be eligible if:** - You have not received prior treatment for advanced disease - You have had more than two prior chemotherapy regimens for advanced disease - Your organ function does not meet required levels Talk to your doctor to see if this trial is right for you.